Adverum Competitors

Delisted . USA . 
Stock . Adverum Biotechnologies
ADVMDelisted Stock  USD 4.36  0.00  0.00%   
Adverum Biotechnologies competes with Artiva Biotherapeutics, Fractyl Health, Sutro Biopharma, Precision BioSciences, and Metagenomi Common; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Adverum Biotechnologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Adverum Biotechnologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Adverum Biotechnologies vs Quince Therapeutics Correlation

Very weak diversification

The correlation between Adverum Biotechnologies and QNCX is 0.47 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Adverum Biotechnologies and QNCX in the same portfolio, assuming nothing else is changed.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Adverum Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
3.094.365.63
Details
Intrinsic
Valuation
LowRealHigh
2.343.614.88
Details

Adverum Biotechnologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adverum Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Adverum and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adverum Biotechnologies does not affect the price movement of the other competitor.

High positive correlations

QNCX
+ 0.95
GUTS
PLRX
+ 0.83
DTIL
ATYR
+ 0.69
ALXO
MGX
+ 0.58
DTIL
ALXO
+ 0.52
STRO
STRO
+ 0.47
ARTV
  

High negative correlations

DTIL
- 0.79
STRO
ALXO
- 0.73
GUTS
QNCX
- 0.69
ALXO
ATYR
- 0.65
GUTS
PLRX
- 0.64
STRO
QNCX
- 0.61
ATYR

Risk-Adjusted Indicators

There is a big difference between Adverum Stock performing well and Adverum Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Adverum Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ARTV  6.41  0.67  0.09  0.56  7.28 
(7.34)
 8.00 
(11.11)
 118.69 
GUTS  5.19 (0.67) 0.00 (0.87) 0.00 
 0.00 
 11.89 
(8.44)
 85.71 
STRO  4.79  1.15  0.21  0.86  4.62 
(5.37)
 11.87 
(7.78)
 29.10 
DTIL  2.97 (0.66) 0.00 (0.71) 0.00 
 0.00 
 5.99 
(7.57)
 15.28 
MGX  3.09 (0.64) 0.00 (0.22) 0.00 
 0.00 
 6.21 
(6.21)
 18.63 
ALXO  5.48  1.08  0.18 (1.86) 5.23 
(6.53)
 13.04 
(9.02)
 23.85 
ATYR  3.94  0.26  0.06  0.28  3.77 
(5.99)
 10.23 
(7.95)
 35.20 
BMEA  4.27 (0.10)(0.01) 0.00  5.37 
(4.28)
 9.38 
(8.33)
 28.51 
PLRX  2.53 (0.60) 0.00 (0.36) 0.00 
 0.00 
 4.59 
(6.82)
 22.72 
QNCX  13.77  2.48  0.12  0.74  18.80 
(17.05)
 16.82 
(16.67)
 369.99 

Adverum Biotechnologies Competitive Analysis

The better you understand Adverum Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adverum Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adverum Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ADVM ARTV GUTS STRO DTIL MGX ALXO ATYR BMEA PLRX
 0.00 
 4.36 
Adverum
 2.50 
 4.10 
Artiva
 6.98 
 0.39 
Fractyl
 3.16 
 16.67 
Sutro
 0.00 
 4.00 
Precision
 0.68 
 1.45 
Metagenomi
 0.00 
 2.27 
Alx
 10.10 
 0.98 
ATyr
 0.00 
 1.33 
Biomea
 1.80 
 1.13 
Pliant
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Very risky
Abnormally volatile
Unstable
Somewhat reliable
Unstable
Dangerous
Dangerous
Very risky
Very risky
Market Performance
(90 Days Performance)
Good
Mild
Weakest
Good
Weakest
Weakest
Fair
Fair
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Average
Risky
Small
High
Strong
Small
Strong
Strong
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
8.03
N/A
N/A
7.44
4.59
N/A
13.23
N/A
16.46
7.69
Net Asset
179.84 M
209.58 M
108.08 M
387.21 M
136.39 M
324.6 M
147.78 M
96.83 M
79.94 M
396.95 M
Profit Margin
N/A
N/A
N/A
-2.05
N/A
-2.87
N/A
N/A
N/A
N/A
EBITDA
(135.51 M)
(64.85 M)
(92.85 M)
(180.45 M)
13.53 M
(83.49 M)
(132.25 M)
(66.37 M)
(142.32 M)
(205.16 M)
Current Valuation
159.14 M
(13.1 M)
48.7 M
112.11 M
77.9 M
(87.63 M)
240.09 M
10.35 M
48.61 M
(113.73 M)
Price To Book
0.93
0.76
1.86
2.11
5.63
0.31
6.49
1.1
5.66
0.34
Operating Margin
N/A
N/A
N/A
-4.01
N/A
-2.64
N/A
-140.76
N/A
N/A
Retained Earnings
(1.07 B)
(246.68 M)
(415.31 M)
(786.87 M)
(482.46 M)
(223 M)
(621.12 M)
(532.05 M)
(387.25 M)
(710.05 M)
Current Asset
260.99 M
N/A
N/A
N/A
174.05 M
N/A
N/A
N/A
N/A
N/A
Beta
0.87
N/A
1.63
1.61
1.31
0.52
0.52
0.58
-0.18
1.35
Number Of Employees
155
106
101
178
67
124
44
56
42
171
Shares Outstanding
22.08 M
24.43 M
153.37 M
85.14 M
24.07 M
37.55 M
131.2 M
97.99 M
70.7 M
61.45 M
Cash Flow From Operations
(92.46 M)
(55.03 M)
(65.52 M)
(191.54 M)
(58.45 M)
(109.07 M)
(121.91 M)
(69.12 M)
(119.89 M)
(155.5 M)
Total Debt
91.7 M
14.35 M
62.5 M
23.15 M
30.05 M
45.78 M
16.98 M
13.28 M
8.77 M
60.19 M
Return On Equity
-4.18
-0.86
-5.18
-18.1
-2.05
-0.41
-1.19
-1.03
-2.09
-0.64
Return On Asset
-0.77
-0.42
-0.51
-0.26
-0.45
-0.19
-0.5
-0.5
-0.75
-0.33
Number Of Shares Shorted
811.4 K
203.79 K
14.9 M
591.3 K
1.38 M
2.42 M
1.14 M
20.43 M
10.16 M
4.18 M
Book Value Per Share
-2.53
6.11
-0.024
-1.02
1.38
4.75
0.84
0.82
0.26
3.26
Current Liabilities
6.57 M
N/A
N/A
N/A
23.86 M
N/A
N/A
N/A
N/A
N/A
Total Asset
179.84 M
209.58 M
108.08 M
387.21 M
136.39 M
324.6 M
147.78 M
96.83 M
79.94 M
396.95 M
Debt To Equity
0.43
N/A
N/A
0.27
0.27
N/A
0.021
N/A
0.017
0.11
Short Ratio
0.93
0.06
1.65
2.37
5.67
8.72
3.36
9.57
8.09
4.05
Target Price
4.88
17.0
5.24
2.69
32.5
9.33
3.33
4.36
7.0
3.25
Shares Owned By Institutions
88.3
74.8
71.41
67.55
52.73
18.01
73.1
57.5
40.18
88.4
Market Capitalization
96.26 M
82.8 M
64.17 M
79.09 M
93.64 M
54.82 M
289.95 M
87.59 M
88.38 M
68.21 M
Price To Earning
-2.1
N/A
N/A
53.08
-6.1
N/A
N/A
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
0.12
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
94.37
214.51
21390.29
2.51
134.15
1.77
5906.24
461.0
N/A
3071.82
Net Income
(130.93 M)
(65.37 M)
(68.69 M)
(227.46 M)
7.17 M
(78.06 M)
(134.85 M)
(64.02 M)
(138.43 M)
(210.3 M)
Earnings Per Share
-8.57
-6.15
-2.32
-2.6
-8.96
-2.39
-2.01
-0.83
-2.25
-2.86
Shares Owned By Insiders
13.21
19.87
1.36
4.68
5.86
29.29
2.9
1.43
8.0
2.4
Revenue
1000 K
251 K
93 K
62.04 M
68.7 M
52.3 M
N/A
235 K
N/A
N/A
Working Capital
108.4 M
176.38 M
51.99 M
211.42 M
80.01 M
220.65 M
115.85 M
66.99 M
46.66 M
329.05 M
Cash And Equivalents
235.84 M
N/A
N/A
225.64 M
184.14 M
N/A
313.37 M
N/A
149.63 M
163.6 M
Cash Per Share
2.37
N/A
N/A
4.33
1.66
N/A
7.69
N/A
5.11
3.36
Gross Profit
(77.12 M)
N/A
3 K
274.15 M
698 K
(65.18 M)
107 K
(61.37 M)
N/A
N/A
Day Typical Price
4.36
4.06
0.4
16.34
3.95
1.46
2.25
0.95
1.31
1.14
Accumulation Distribution
N/A
6520.64
320698.0
8168.36
9204.76
10735.99
43743.75
338881.0
62650.99
65800.68
Daily Balance Of Power
0.0
0.303
(0.73)
0.4359
N/A
(0.10)
N/A
0.6915
N/A
0.25
Period Momentum Indicator
N/A
0.1
(0.03)
0.51
N/A
(0.01)
N/A
0.0899
N/A
0.02
Rate Of Daily Change
1.0
1.02
0.93
1.03
1.0
0.99
1.0
1.1
1.0
1.02
Day Median Price
4.36
4.04
0.41
16.18
3.92
1.47
2.24
0.94
1.31
1.14
Price Action Indicator
N/A
0.11
(0.03)
0.75
0.08
(0.03)
0.035
0.0898
0.025
N/A
Coefficient Of Variation
1218.59
1709.29
(1,656)
505.0
(657.41)
(868.13)
626.33
1723.58
70031.57
(689.00)
Mean Deviation
3.39
6.41
5.19
4.79
2.97
3.09
5.48
3.94
4.27
2.53
Jensen Alpha
0.4156
0.6721
(0.67)
1.15
(0.66)
(0.64)
1.08
0.258
(0.1)
(0.60)
Total Risk Alpha
0.034
(0.22)
(1.39)
0.7716
(0.90)
(0.82)
0.5528
(0.10)
(0.41)
(0.78)
Sortino Ratio
0.0952
0.0891
N/A
0.2074
N/A
N/A
0.1785
0.0594
(0.01)
N/A
Downside Variance
17.15
60.47
N/A
32.42
N/A
N/A
30.31
20.35
31.88
N/A
Standard Deviation
5.66
13.04
10.28
6.32
3.91
4.28
6.59
5.82
5.47
3.51
Kurtosis
8.42
35.93
28.27
0.8669
0.6013
2.85
(0.73)
6.16
0.3705
3.72
Potential Upside
10.34
8.0
11.89
11.87
5.99
6.21
13.04
10.23
9.38
4.59
Treynor Ratio
0.7042
0.5599
(0.87)
0.8621
(0.71)
(0.22)
(1.86)
0.2813
(0)
(0.36)
Maximum Drawdown
40.97
118.69
85.71
29.1
15.28
18.63
23.85
35.2
28.51
22.72
Variance
32.0
169.96
105.71
39.9
15.31
18.36
43.45
33.9
29.91
12.29
Market Risk Adjusted Performance
0.7142
0.5699
(0.86)
0.8721
(0.70)
(0.21)
(1.85)
0.2913
0.0086
(0.35)
Risk Adjusted Performance
0.0748
0.0566
(0.04)
0.1685
(0.11)
(0.08)
0.1376
0.0554
0.0097
(0.11)
Skewness
1.92
5.01
(4.36)
0.4953
(0.34)
0.0359
0.3322
1.8
0.2445
(0.99)
Semi Deviation
3.7
7.28
N/A
4.62
N/A
N/A
5.23
3.77
5.37
N/A
Information Ratio
0.0697
0.0531
(0.07)
0.1869
(0.17)
(0.13)
0.149
0.046
(0.01)
(0.17)
Value At Risk
(6.79)
(11.11)
(8.44)
(7.78)
(7.57)
(6.21)
(9.02)
(7.95)
(8.33)
(6.82)
Expected Short fall
(4.59)
(7.34)
N/A
(5.37)
N/A
N/A
(6.53)
(5.99)
(4.28)
N/A
Downside Deviation
4.14
7.78
N/A
5.69
N/A
N/A
5.51
4.51
5.65
N/A
Semi Variance
13.68
52.99
N/A
21.32
N/A
N/A
27.33
14.19
28.88
N/A

Adverum Biotechnologies Competition Performance Charts

Five steps to successful analysis of Adverum Biotechnologies Competition

Adverum Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Adverum Biotechnologies in relation to its competition. Adverum Biotechnologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Adverum Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Adverum Biotechnologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Adverum Biotechnologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Adverum Biotechnologies position

In addition to having Adverum Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Penny Thematic Idea Now

Penny
Penny Theme
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Consideration for investing in Adverum Stock

If you are still planning to invest in Adverum Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adverum Biotechnologies' history and understand the potential risks before investing.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stocks Directory
Find actively traded stocks across global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY